GAMMA Investing LLC Increases Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

GAMMA Investing LLC lifted its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 5,187.8% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 91,796 shares of the company's stock after buying an additional 90,060 shares during the quarter. GAMMA Investing LLC owned approximately 0.20% of Pacira BioSciences worth $2,281,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Renaissance Technologies LLC increased its holdings in Pacira BioSciences by 0.7% in the 4th quarter. Renaissance Technologies LLC now owns 1,992,601 shares of the company's stock valued at $37,541,000 after acquiring an additional 13,604 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Pacira BioSciences by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,091,970 shares of the company's stock valued at $20,578,000 after purchasing an additional 5,071 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Pacira BioSciences in the fourth quarter worth about $20,266,000. Nuveen Asset Management LLC lifted its position in shares of Pacira BioSciences by 109.9% in the fourth quarter. Nuveen Asset Management LLC now owns 625,917 shares of the company's stock worth $11,792,000 after buying an additional 327,754 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in Pacira BioSciences by 30.8% during the fourth quarter. Northern Trust Corp now owns 616,891 shares of the company's stock valued at $11,622,000 after buying an additional 145,205 shares during the last quarter. Institutional investors own 99.73% of the company's stock.

Pacira BioSciences Trading Up 0.2%

Shares of Pacira BioSciences stock traded up $0.05 during trading on Tuesday, hitting $24.39. The stock had a trading volume of 351,381 shares, compared to its average volume of 970,754. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $29.61. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.41 and a quick ratio of 1.99. The firm's fifty day simple moving average is $25.50 and its 200-day simple moving average is $23.73. The stock has a market cap of $1.13 billion, a PE ratio of -10.70 and a beta of 0.52.

Insider Activity at Pacira BioSciences

In related news, SVP Lauren Riker sold 5,578 shares of the company's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total value of $146,199.38. Following the completion of the sale, the senior vice president now directly owns 59,564 shares of the company's stock, valued at $1,561,172.44. This represents a 8.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.40% of the stock is owned by company insiders.

Analyst Ratings Changes

PCRX has been the topic of a number of research reports. Barclays lifted their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Wall Street Zen upgraded shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research report on Friday, June 6th. Needham & Company LLC lowered their price objective on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Finally, HC Wainwright boosted their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a report on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $26.44.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.